Resource Center

www.lls.org/resourcecenter

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:

donate

May 21, 2013 - Living with Slow-Growing Lymphoma

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: Tuesday May 21, 2013
Time: 1:00 p.m. - 2:30 p.m. ET
Location: Telephone/Web
Read: Program Slides | Transcript
Listen: Presentation | Q&A Session | Extended Q&A
Access: Virtual Lecture

Topics Covered

  • Follicular and other slow-growing lymphomas
  • Current and emerging treatments, including stem cell transplant, for follicular and other slow-growing lymphomas
  • The role of clinical trials in the advancement of treatment
  • Patient-provider communications about treatment options, including clinical trials
  • Patient-provider communications about side effects management

Speaker

Stephen M. Ansell, MD, PhD
Professor of Medicine
Division of Hematology
Department of Internal Medicine
Mayo Clinic
Rochester, MN

Questions Asked by the Slow-Growing Lymphoma Community

  • What does grade 3 follicular lymphoma mean and how are follicular lymphomas graded?
  • Could you speak a little bit more about maintenance rituximab (Rituxan®) therapy?
  • Are six rounds of Ritxuan and bendamustine (Treanda®) necessary or can one get by on fewer rounds if the therapy is working?
  • Would Rituxan maintenance be a good idea or would watch and wait be a better treatment option after a second relapse with follicular lymphoma?
  • Please talk about the role and outcomes of radioimmunotherapy as a treatment option for slow-growing lymphomas.
  • What would be the best sort of chemical combination to use after relapsing with small B-cell lymphocytic lymphoma? 
  • Does age at diagnosis change the prognosis or the course of the disease?
  • Is it possible to become resistant to Rituxan if a patient hasn't been treated with it for a while?
  • If a patient is resistant to Rituxan, is the patient likely to be refractory to ofatumumab (Arzerra®) as well as the other CD20 antibodies?
  • Is follicular non-Hodgkin lymphoma inherited?
  • Can Rituxan increase LDH levels months after chemo treatment? 
  • What is considered a relapse after Rituxan maintenance for two years?
  • Can one have an allogeneic transplant if their bone marrow is involved with the lymphoma?
  • If a patient has a diagnosis of subcutaneous panniculitis-like T-cell lymphoma and is treated with cyclosporine with a combination of prednisone, was weaned off the cyclosporine but still on maintenance prednisone, would the patient be able to go back on the cyclosporine if it worked before?
  • Besides the BTK inhibitor, are there any other new tyrosine kinase inhibitors that show promise?
  • How do treatments affect the bone marrow? 
  • When will some of these novel treatments and drugs in clinical trials be available more widely?
  • Do you have to be near a clinical trial site to participate?
  • What are CDK inhibitors?
  • Should I be concerned about radiation from the monitoring scans?
  • Are severe leg cramps a side effect of cancer treatment?
  • Can you go back a stage? For instance, if you're in stage III, can you go back to stage II if you have a lymph node removed?
  • Can you talk about ibrutinib and what would it mean for Waldenstrom's macroglobulinemia?
  • Would Medicare pay for ibrutinib if it is approved or only for the specific lymphomas it's been approved for?
  • Is it possible to be over-treated?
  • What percentages of people are in remission from follicular lymphoma?
  • If lymphoma is in the bone marrow, will it ever spread to other areas in the body?
  • Is Idiopathic thrombocytopenic purpura (ITP) related to low grade lymphoma or is it something totally different?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by grants from Genentech and Biogen Idec and Spectrum Pharmaceuticals.

last updated on Wednesday, April 23, 2014
btn_sharethis